Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Free Cash Flow (2020 - 2026)

PROCEPT BioRobotics has reported Free Cash Flow over the past 7 years, most recently at -$39.2 million for Q1 2026.

  • Quarterly Free Cash Flow fell 108.27% to -$39.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$78.7 million through Mar 2026, up 7.97% year-over-year, with the annual reading at -$58.3 million for FY2025, 41.4% up from the prior year.
  • Free Cash Flow was -$39.2 million for Q1 2026 at PROCEPT BioRobotics, down from -$12.2 million in the prior quarter.
  • Over five years, Free Cash Flow peaked at -$12.2 million in Q4 2025 and troughed at -$39.2 million in Q1 2026.
  • The 5-year median for Free Cash Flow is -$18.8 million (2023), against an average of -$22.9 million.
  • Year-over-year, Free Cash Flow tumbled 115.75% in 2023 and then soared 58.73% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$26.0 million in 2022, then increased by 27.73% to -$18.8 million in 2023, then tumbled by 56.78% to -$29.5 million in 2024, then soared by 58.73% to -$12.2 million in 2025, then plummeted by 221.82% to -$39.2 million in 2026.
  • Per Business Quant, the three most recent readings for PRCT's Free Cash Flow are -$39.2 million (Q1 2026), -$12.2 million (Q4 2025), and -$13.5 million (Q3 2025).